Trial · NCT03852719
Adverse event totals27
The totals the trial posted for each group.
1 to 20 of 27
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Delayed Treatment (Baseline to Week 48) | 0 | 51 |
| Total, all-cause mortality | Bulevirtide 2 mg/Day (Baseline to Week 48) | 0 | 49 |
| Total, all-cause mortality | Bulevirtide 10 mg/Day (Baseline to Week 48) | 0 | 50 |
| Total, all-cause mortality | Bulevirtide 2 mg/Day (Baseline to Week 144) | 0 | 49 |
| Total, all-cause mortality | Bulevirtide 10 mg/Day (Baseline to Week 144) | 0 | 50 |
| Total, all-cause mortality | Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) | 1 | 50 |
| Total, all-cause mortality | Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) | 0 | 46 |
| Total, all-cause mortality | Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 0 | 47 |
| Total, all-cause mortality | Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 0 | 49 |
| Total, other adverse events | Delayed Treatment (Baseline to Week 48) | 30 | 51 |
| Total, other adverse events | Bulevirtide 2 mg/Day (Baseline to Week 48) | 35 | 49 |
| Total, other adverse events | Bulevirtide 10 mg/Day (Baseline to Week 48) | 41 | 50 |
| Total, other adverse events | Bulevirtide 2 mg/Day (Baseline to Week 144) | 44 | 49 |
| Total, other adverse events | Bulevirtide 10 mg/Day (Baseline to Week 144) | 46 | 50 |
| Total, other adverse events | Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) | 41 | 50 |
| Total, other adverse events | Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) | 31 | 46 |
| Total, other adverse events | Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 33 | 47 |
| Total, other adverse events | Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 34 | 49 |
| Total, serious adverse events | Delayed Treatment (Baseline to Week 48) | 1 | 51 |
| Total, serious adverse events | Bulevirtide 2 mg/Day (Baseline to Week 48) | 2 | 49 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03852719/event-totals